5/4/2007 2:35:29 AM
NEW YORK (Reuters Health) - The use of diabetes drugs called thiazolidinediones, such as rosiglitazone (Avandia) and pioglitazone (Actos), may reduce the risk of lung cancer, according to a report in the Journal of Clinical Oncology.
These are preliminary findings, Dr. Rangaswamy Govindarajan from the University of Arkansas for Medical Sciences, Little Rock, told Reuters Health. "Physicians should be cautioned not to start using these agents for cancer prevention."
>>> Discuss This Story
comments powered by